Alogliptin benzoate for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 553-563

  Rendell, Marc ^a,b   Drincic, Andjela ^c   Andukuri, Radha ^a  

^a Creighton Diabetes Center   (United States)

^b Association of Diabetes Investigators   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

DPP 4 inhibitors; GLP 1, alogliptin; Incretins; Linagliptin; Sitagliptin saxagliptin; Vildagliptin

Indexed keywords

ALOGLIPTIN; ATORVASTATIN; CIMETIDINE; CYCLOSPORIN; DIGOXIN; DILTIAZEM; EXENDIN 4; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETOCONAZOLE; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO; RIFAMPICIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; WARFARIN;

ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIDIABETIC ACTIVITY; BODY WEIGHT; CONSTIPATION; CORONARY ARTERY DISEASE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EXFOLIATIVE DERMATITIS; FOOD INTAKE; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN NECROSIS; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT CHANGE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URACIL;

EID: 84857343528     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.656088     Document Type: Review

References (89)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57 (Pubitemid 46711096)
3. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31:233-42 (Pubitemid 40961520)
4. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000;66:91-103 (Pubitemid 30025456)
5. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1) cells. J Endocrinol 2002;174:233-46 (Pubitemid 34965762)
6. Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-70 (Pubitemid 32826409)
7. Ross SA, Brown JC, Dupre J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977;26:525-9 (Pubitemid 8124531)
8. Vilsb'll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13 (Pubitemid 32195226)
9. Vilsb'll T, Agers' H, Lauritsen T, et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 2006;137:168-72 (Pubitemid 44838981)
10. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001;50:1004-11 (Pubitemid 32374530)
11. Zhou J, Livak MF, Bernier M, et al. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab 2007;293:E538-473
12. Pratley R. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am 2006;35(Suppl 1):6-11 (Pubitemid 46561193)
13. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512
14. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52 (Pubitemid 16162741)
15. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7 (Pubitemid 23037285)
16. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006;91:1916-23
17. Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 2005;128:149-57 (Pubitemid 40380915)
18. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7 (Pubitemid 23037285)
19. Drab SR. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy 2009;29:43-54S
20. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009;43:1433-44
21. Iltz JL, Baker DE, Setter SM, Keith Campbell R. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006;28:652-65 (Pubitemid 44067260)
22. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76 (Pubitemid 40115912)
23. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616-20 (Pubitemid 40591214)
24. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
25. Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97 (Pubitemid 46440314)
26. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569-83
27. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-50 (Pubitemid 351294402)
28. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69
29. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96 (Pubitemid 351294398)
30. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008;68:2387-409
31. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23 (Pubitemid 46580622)
32. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15
33. Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008;40:892-5
34. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
35. Borja-Hart NL, Whalen KL. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann Pharmacother 2010;44:1046-53
36. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86 (Pubitemid 351524285)
37. Goke B, Gallwitz B, Eriksson J, et al. D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31
38. Karyekar C, Donovan M, Allen E, et al. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med 2011; 123:63-70
39. Chacra AR, Tan GH, Ravichandran S, et al. CV181040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8:150-9
40. Hollander PL, Li J, Frederich R, CV181013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011;8:125-35
41. Sarashina A, Sesoko S, Nakashima M, et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010;32:1188-20
42. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409-19
43. Toth PP. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Postgrad Med 2011;123:46-53
44. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
45. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9
46. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300 (Pubitemid 46799241)
47. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Dis Obes 2009;2:117-26
48. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
49. Christopher R, Davenport M, Gwaltney S, et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys [abstract]. Diabetes 2006;55(Suppl 1):A107-8
50. Karim A, Bridson W, Fleck P, et al. Disposition of the dipeptidyl peptidase-4 inhibitor[14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects [abstract]. AAPS J 2007;9(S2):T3552
51. Covington P, Christopher R, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-27 (Pubitemid 351492530)
52. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499-512 (Pubitemid 351483925)
53. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010;48:46-58
54. Fleck P, Karim A, Harris S, et al. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects [abstract]. Presented at: American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, IL. Abstract 2135-PO
55. Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009;49:1210-19
56. Covington P, Christopher R, Davenport M, et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects [abstract]. Diabetes 2007;56(Suppl 1):A541-2
57. Karim A, Fleck P, Joseph M, et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride [abstract]. Diabetes 2007;56(Suppl 1):A536
58. Karim A, Harris S, Fleck P, et al. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects [abstract 105]. J Clin Pharmacol 2007;47:1207
59. Karim A, Harris S, Fleck P, et al. Assesment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state [abstract106]. J Clin Pharmacol 2007;47:1207
60. Karim A, Chiselko P, Fleck P, et al. Lack of effect of cyclosporine on the single dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects [abstract]. Clin Pharmacol Ther 2008;83(Suppl 1):S13
61. Karim A, Copa A, Fleck P, et al. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (ORTHONOVUM( R) 1/35) in healthy adult female subjects [abstract]. Clin Pharmacol Ther 2008;83(Suppl):S13
62. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects [abstract]. Clin Pharmacol Ther 2008;83(Suppl 1):S14
63. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects [abstract]. Clin Pharmacol Ther 2008;83(Suppl 1):S12-13
64. Defronzo R, Fleck P, Wilson C, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
65. Pratley R, Kipnes M, Fleck P, et al. Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-76
66. Nauck M, Ellis G, Fleck P, et al. Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55
67. Pratley RE, Reusch JE, Fleck PR, et al. Alogliptin Study 009 Group Collaborators. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71
68. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145-52
69. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008;4:753-68
70. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
71. EMEA. Summary of product characteristics of vildagliptin. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/ medicines/000771/human-med-000803. jsp&murl=menus/medicines/medicines. jsp&jsenabled=true [Last accessed 21 January 2012]
72. Saxagliptin (BMS-477118) FDA's Endocrinologic and Metabolic Drugs. Advisory Committee Briefing Document for April 2009 Meeting NDA 22-350; 2 March 2009
73. EMEA. Scientific discussion on vildagliptin: pharmacodynamics, pharmacokinetics, efficacy and safety. Available from: http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000771/ human-med-000803.jsp&murl=menus/ medicines/medicines.jsp&jsenabled=true [Last accessed 21 January 2012]
74. Merck shares Januvia safety data following FDA decision to delay approval of rival drug. Available from: http://www.hcplive.com/publications/ internal-medicine-world-report/2006/ 2006-12/2006-12-45 [Last accessed 21 January 2012]
75. Janumet (sitagliptin/metformin HCl) Tablets Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - January 2008. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/Safety-RelatedDrug LabelingChanges/ucm106669.htm [Last accessed 21 January 2012]
76. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
77. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90 (Pubitemid 350302434)
78. Reinhold D, Goihl A, Wrenger S, et al. Role of dipeptidyl peptidase IV (DPP IV)-like enzymes in T lymphocyte activation: investigations in DPP IV/ CD26-knockout mice. Clin Chem Lab Med 2009;47:268-74
79. Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-61
80. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31
81. Olansky L. Do incretin-based therapies cause acute pancreatitis? J Diabetes Sci Technol 2010;4:228-9
82. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150-6
83. Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) [09-25-2009]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafety InformationforPatientsandProviders/ DrugSafetyInformationforHeathcare Professionals/ucm183764.htm [Last accessed 21 January 2012]
84. Karim A, Fleck P, Hetman L, et al. Single dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment[poster 538 P]. Diabetes 2008;57(Suppl 1):A160
85. Karim A, Fleck P, Dorsey D, et al. Single dose pharmacokinetics of alogliptin benzoate(SYR-322) in subjects with moderate hepatic impairment [abstract 107]. J Clin Pharmacol 2007;47:1207
86. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94 (Pubitemid 36775376)
87. Ismail-Beigi F, Craven T, Banerji MA, et al. ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30
88. Gerstein HC, Miller ME, Genuth S, et al. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28
89. Riddle MC. Counterpoint: intensive glucose control and mortality in ACCORD - still looking for clues. Diabetes Care 2010; 33:2722-4